Back to Search
Start Over
Dare Bioscience Announces New Development Program, DARE-PDM1, as a Potential First-in-Category Treatment for Primary Dysmenorrhea
- Source :
- Plus Company Updates. December 14, 2022
- Publication Year :
- 2022
-
Abstract
- SAN DIEGO: Dare Bioscience, Inc. has issued the following news release: Dare Bioscience, Inc. (NASDAQ: DARE), a leader in women's health innovation, today announced a new development program targeted at [...]
Details
- Language :
- English
- Database :
- Gale General OneFile
- Journal :
- Plus Company Updates
- Publication Type :
- News
- Accession number :
- edsgcl.730321931